Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth

Br J Cancer. 1996 Apr;73(7):872-6. doi: 10.1038/bjc.1996.155.


Histamine has recently been shown to be a growth factor for some gastric and colorectal cancer cells. Previous studies have shown that cimetidine blocks in vitro and in vivo histamine-stimulated growth and cAMP release from the human colonic cancer cell line, C170. In this study, ranitidine, another H2 receptor antagonist, did not affect either basal or histamine-stimulated in vitro proliferation of C170, and failed to prevent cAMP release in vitro. Ranitidine did not inhibit in vivo growth of C170 at a dose of 1, 10, 25, 50 or 100 mg/kg, in contrast to 50 mg/kg/day cimetidine, which produced 39.3% inhibition of tumour volume (p<0.01) after 23 days' treatment. Ranitidine did not inhibit in vivo histamine-stimulated growth of C170 cells . LIM2412, another colonic cancer cell line, was significantly stimulated by both cimetidine and ranitidine in vivo. Ranitidine had no effect on in vitro cell proliferation.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / pathology*
  • Animals
  • Cell Division / drug effects
  • Cimetidine / pharmacology*
  • Colonic Neoplasms / pathology*
  • Cyclic AMP / biosynthesis
  • Drug Interactions
  • Histamine / pharmacology
  • Histamine H2 Antagonists / pharmacology*
  • Humans
  • Male
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • Ranitidine / pharmacology*
  • Stimulation, Chemical
  • Tumor Cells, Cultured / drug effects


  • Histamine H2 Antagonists
  • Cimetidine
  • Histamine
  • Ranitidine
  • Cyclic AMP